Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMeridian Medicaid Pancrelipase Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentMeridian Illinois MedicaidPolicy MDN.CP.PMN.226

    Pancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep)

    Customize your policy alerts

    Sign up for meridian Policy MDN.CP.PMN.226 alerts

    Get alerted when Policy MDN.CP.PMN.226 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Meridian Illinois Medicaid coverage and prior authorization for Creon, Pancreaze, Pertzye, Viokace, and Zenpep for adult and pediatric members with exocrine pancreatic insufficiency.

    Policy Summary
    PayerMeridian Illinois Medicaid
    PolicyPancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep)
    Policy CodePolicy MDN.CP.PMN.226
    Change TypeAdministrative/reference update
    Effective DateOct 15, 2025
    Last ReviewOct 25, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes, laboratory results, or other clinical information supporting that all approval criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Covered pancrelipase products
    12 monthsApproval duration
    2,500 units/kgMaximum dose per meal
    10,000 units/kgMaximum daily dose by weight

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    None
    Material changes

    Coverage Criteria

    Initial therapy: pancreatic insufficiency

    Covered when all applicable criteria are met.

    Initial pancreatic insufficiency approval

    • Diagnosis: The member has a diagnosis of exocrine pancreatic insufficiency, such as insufficiency due to cystic fibrosis, chronic pancreatitis, or pancreatectomy.
    • Product-specific requirements: If Pertzye is requested, the member has failed Creon unless Creon is contraindicated or caused clinically significant adverse effects. If Pancreaze, Viokace, or Zenpep is requested, the member has failed Creon unless Creon is contraindicated or caused clinically significant adverse effects; if the member is unable to take Creon, the member has also failed Pertzye unless Pertzye is contraindicated or caused clinically significant adverse effects.

      Apply the requirements for the requested product.

    • Viokace requirements when applicable: If Viokace is requested, the member is at least 18 years old and Viokace is prescribed concurrently with a proton pump inhibitor.Age ≥ 18 years

      Applies only when Viokace is requested.

    • Dose limit: The dose does not exceed one of the following limits.2,500 lipase units/kg per meal OR 10,000 lipase units/kg per day OR 4,000 lipase units/g of fat ingested per day

    Other diagnoses or indications

    Other diagnoses or indications must meet one of the following pathways.

    • Recent label change: The drug has undergone a label change within the last 6 months, such as a newly approved indication, age expansion, or new dosing regimen, that is not reflected in this policy; refer to the applicable Medicaid policy.

      Use CP.PMN.255 for drugs on the Medicaid preferred drug list; use CP.PMN.16 for drugs not on the Medicaid preferred drug list.

    • Other use not specifically listed as unauthorized: The requested use, such as the diagnosis, age, or dosing regimen, is not specifically listed under the policy's unauthorized indications, and the recent-label-change pathway does not apply; refer to the Medicaid off-label use policy CP.PMN.53.

    Continuation therapy: pancreatic insufficiency

    Continued therapy is covered when all applicable criteria are met.

    Continued pancreatic insufficiency therapy

    • Prior coverage or continuity of care

      • The member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
      • The member is currently receiving the medication and is enrolled in a state and product subject to continuity-of-care regulations.

        Refer to the applicable state-specific addenda for CC.PHARM.03A and CC.PHARM.03B.

    • Positive response: The member is responding positively to therapy.

      Examples include reduced steatorrhea and associated gastrointestinal symptoms; increased weight, muscle mass, or muscle function; or improved fat-soluble vitamin levels.

    Other continued-therapy diagnoses or indications

    Other continued-therapy diagnoses or indications must follow the applicable policy pathway.

    • Recent label change: The drug has undergone a label change within the last 6 months that is not reflected in this policy; refer to the applicable Medicaid policy.

      Use CP.PMN.255 for drugs on the Medicaid preferred drug list or CP.PMN.16 for drugs not on the Medicaid preferred drug list.

    • Other use not specifically listed as unauthorized: The requested use, such as the diagnosis, age, or dosing regimen, is not specifically listed under the policy's unauthorized indications and the recent-label-change pathway does not apply; refer to the Medicaid off-label use policy CP.PMN.53.

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless sufficient documentation demonstrates efficacy and safety under the applicable Medicaid off-label use policy or evidence of coverage documents.

    Dose and Coding Parameters

    Maximum dose per meal
    Maximum dose2,500 lipase units/kg per meal
    Maximum dose per day by body weight
    Maximum dose10,000 lipase units/kg per day
    Maximum dose per day by fat intake
    Maximum dose4,000 lipase units/g of fat ingested per day

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for pancrelipase products. The provider must submit documentation supporting that the member meets all applicable approval criteria.

    • Applies to Creon, Pancreaze, Pertzye, Viokace, and Zenpep.
    • Submit the authorization request with supporting clinical documentation.
    Step Therapy

    Pertzye Requires Creon Failure

    For requests for Pertzye, the member must have failed Creon, unless Creon is contraindicated or caused clinically significant adverse effects.

    • Document Creon failure, contraindication, or clinically significant adverse effects.

    Background

    Pancrelipase is a porcine-derived combination of lipases, proteases, and amylases used to replace pancreatic digestive enzymes. This policy addresses the covered products Creon, Pancreaze, Pertzye, Viokace, and Zenpep for treatment of exocrine pancreatic insufficiency in adult and pediatric patients, including insufficiency associated with cystic fibrosis, chronic pancreatitis, or pancreatectomy. Viokace is covered for adults with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy when prescribed concurrently with a proton pump inhibitor.

    Definitions

    Pancrelipase
    DefinitionA combination of porcine-derived lipases, proteases, and amylases.
    Exocrine pancreatic insufficiency
    DefinitionInsufficient pancreatic digestive enzyme function.
    Policy examplesExocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, or pancreatectomy.
    Concurrent proton pump inhibitor therapy
    RequirementWhen Viokace is requested, it must be prescribed concurrently with a proton pump inhibitor.

    Initial Therapy Criteria

    Pancreatic insufficiency initial approval

    Initial therapy requires all applicable criteria.

    Initial pancreatic insufficiency approval

    • Diagnosis: The member has a diagnosis of exocrine pancreatic insufficiency, such as insufficiency due to cystic fibrosis, chronic pancreatitis, or pancreatectomy.
    • Product-specific requirements: If Pertzye is requested, the member has failed Creon unless Creon is contraindicated or caused clinically significant adverse effects. If Pancreaze, Viokace, or Zenpep is requested, the member has failed Creon unless Creon is contraindicated or caused clinically significant adverse effects; if the member is unable to take Creon, the member has also failed Pertzye unless Pertzye is contraindicated or caused clinically significant adverse effects.

      Apply the requirements for the requested product.

    • Viokace requirements when applicable:

    Continuation Criteria

    Pancreatic insufficiency continuation

    Continued therapy requires all applicable criteria.

    Continued pancrelipase therapy

    • Prior coverage or continuity of care

      • The member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
      • The member is currently receiving the medication and is enrolled in a state and product subject to continuity-of-care regulations.

        Refer to the applicable state-specific addenda for CC.PHARM.03A and CC.PHARM.03B.

    • Positive response: The member is responding positively to therapy.

      Examples include reduced steatorrhea and associated gastrointestinal symptoms; increased weight, muscle mass, or muscle function; or improved fat-soluble vitamin levels.

    Step Therapy

    StepRequested productRequirement
    1
    Pertzye
    Failure of Creon, unless Creon is contraindicated or clinically significant adverse effects are experienced.
    1
    Pancreaze, Viokace, or Zenpep
    Failure of Creon, unless Creon is contraindicated or clinically significant adverse effects are experienced. If unable to take Creon, failure of Pertzye is also required unless Pertzye is contraindicated or clinically significant adverse effects are experienced.

    Quantity Limits

    Creon, Pancreaze, Pertzye, Viokace, or Zenpep
    Maximum dose per meal2,500 lipase units/kg per meal
    Creon, Pancreaze, Pertzye, Viokace, or Zenpep
    Maximum dose per day by body weight10,000 lipase units/kg per day
    Creon, Pancreaze, Pertzye, Viokace, or Zenpep
    Maximum dose per day by fat intake4,000 lipase units/g of fat ingested per day
    Policy Summary
    PayerMeridian Illinois Medicaid
    PolicyPancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep)
    Policy CodePolicy MDN.CP.PMN.226
    Change TypeAdministrative/reference update
    Effective DateOct 15, 2025
    Last ReviewOct 25, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes, laboratory results, or other clinical information supporting that all approval criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaDose and Coding ParametersProvider Actions and Authorization RequirementsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep TherapyQuantity Limits
    Dose increase limit: If a dose increase is requested, the new dose does not exceed one of the following limits.2,500 lipase units/kg per meal OR 10,000 lipase units/kg per day OR 4,000 lipase units/g of fat ingested per day
    Step Therapy

    Step Therapy for Pancreaze, Viokace, and Zenpep

    For requests for Pancreaze, Viokace, or Zenpep, the member must have failed Creon, unless Creon is contraindicated or caused clinically significant adverse effects. If the member is unable to take Creon, the member must also have failed Pertzye, unless Pertzye is contraindicated or caused clinically significant adverse effects.

    • Document Creon failure, contraindication, or clinically significant adverse effects.
    • When the member is unable to take Creon, document Pertzye failure, contraindication, or clinically significant adverse effects.
    Documentation Required

    Clinical Documentation Required

    The provider must submit clinical documentation supporting that the member meets all approval criteria.

    • Office chart notes.
    • Laboratory results.
    • Other relevant clinical information.
    Documentation Required

    Initial Request Support

    Initial requests must include documentation supporting the diagnosis and any applicable product-specific requirements, including prior product failures, contraindications, or clinically significant adverse effects.

    • Diagnosis of exocrine pancreatic insufficiency, such as from cystic fibrosis, chronic pancreatitis, or pancreatectomy.
    • For applicable products, document Creon failure or the applicable contraindication or adverse effect.
    • When the member is unable to take Creon and the request is for Pancreaze, Viokace, or Zenpep, document Pertzye failure or the applicable contraindication or adverse effect.
    • For Viokace, document age 18 years or older and concurrent proton pump inhibitor use.
    • Document that the requested dose does not exceed the applicable policy limits.
    Documentation Required

    Continuation Request Support

    Continuation requests must document prior approval or qualifying continuity of care, positive response to therapy, and the requested dosing when a dose increase is requested.

    • Document that the member is receiving the medication through the Centene benefit or previously met initial approval criteria, or qualifies under applicable state and product continuity-of-care regulations.
    • Document positive response, such as reduced steatorrhea or gastrointestinal symptoms, weight or muscle gains, improved muscle function, or improved fat-soluble vitamin levels.
    • For a dose increase, document that the new dose remains within policy limits.
    Denial Risk

    Failure to Meet Initial Approval Criteria

    An initial request may be denied when the member does not meet all applicable initial approval criteria or the submitted documentation does not establish those criteria.

    • No documented diagnosis of exocrine pancreatic insufficiency.
    • Required Creon or Pertzye failure, contraindication, or clinically significant adverse-effect exception is not established.
    • Applicable Viokace age or concurrent proton pump inhibitor requirements are not met.
    • Requested dose exceeds the applicable policy limits.
    Denial Risk

    Failure to Meet Continued Therapy Criteria

    A continuation request may be denied when the member does not meet the required continuation criteria or the submitted documentation does not establish them.

    • No documented prior approval, prior satisfaction of initial criteria, or qualifying continuity-of-care eligibility.
    • No documented positive response to therapy.
    • For a requested dose increase, the new dose exceeds the applicable policy limits.
    Denial Risk

    Non-FDA-Approved Indications

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy, unless sufficient documentation of efficacy and safety supports coverage under the applicable off-label use policy or evidence of coverage documents.

    • For Medicaid, refer to off-label use policy CP.PMN.53.
    • For other coverage, refer to the applicable evidence of coverage documents.
    If Viokace is requested, the member is at least 18 years old and Viokace is prescribed concurrently with a proton pump inhibitor.
    Age ≥ 18 years

    Applies only when Viokace is requested.

  1. Dose limit: The dose does not exceed one of the following limits.2,500 lipase units/kg per meal OR 10,000 lipase units/kg per day OR 4,000 lipase units/g of fat ingested per day
  2. Dose increase limit: If a dose increase is requested, the new dose does not exceed one of the following limits.2,500 lipase units/kg per meal OR 10,000 lipase units/kg per day OR 4,000 lipase units/g of fat ingested per day